Phase I/II trial of RAD001 plus Nexavar for patients with metastatic renal cell carcinoma.
Latest Information Update: 05 Jul 2021
At a glance
- Drugs Everolimus (Primary) ; Sorafenib
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2008 Planned end date changed from 1 Apr 2009 to 1 Aug 2009.
- 24 Aug 2008 The expected completion date for this trial is now 1 Apr 2009 as reported by ClinicalTrials.gov.